Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.66 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6998196 | 0.93 | EGFR (0.57) | EGFRMKNK2CLK4MEN1USP2 | |
| SCHEMBL6989068 | 0.90 | EGFR (0.57) | EGFRMKNK2CLK4ERBB2AURKB | |
| SCHEMBL6990938 | 0.90 | EGFR (0.54) | EGFRMKNK2ERBB2HTT | |
| SCHEMBL30556170 | 0.88 | EGFR (0.51) | EGFRMKNK2MAP4K4 | |
| SCHEMBL6996883 | 0.87 | EGFR (0.51) | EGFRCLK4MAP4K4LTKMAPK8 | |
| SCHEMBL6993872 | 0.87 | EGFR (0.69) | EGFRHIF1AMAPK1HTT | |
| SCHEMBL6993612 | 0.86 | EGFR (0.56) | EGFRMKNK2CLK4ERBB2AURKB | |
| SCHEMBL8320084 | 0.86 | EGFR (0.70) | EGFRERBB2MEN1KMT2A | |
| SCHEMBL8315330 | 0.86 | EGFR (0.57) | EGFRABL1ERBB2MAPK14MEN1 | |
| SCHEMBL8314880 | 0.86 | EGFR (0.53) | EGFRABL1AURKBABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849734-B2 | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-01 | — | — | US | disclosed |
| EP-1383770-B1 | METHOD FOR THE PRODUCTION OF 4,6-DIAMINOPYRIMIDO 5,4-D]PYRIMIDINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-09-22 | — | — | EP | disclosed |
| US-20040059114-A1 | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| US-6680384-B2 | REACTING TETRACHLOROPYRIMIDO(5,4-D)PYRIMIDINE WITH AMINE COMPOUND; REDUCING TO FORM 4,6-DIAMINOPYRIMIDO(5,4-D)PYRIMIDINE COMPOUND | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-01-20 | — | — | US | disclosed |
| US-20020198380-A1 | Process for preparing 4,6-diaminopyrimido[5,4-d]pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-26 | — | — | US | disclosed |
| EP-0779888-B1 | PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-04-28 | — | — | EP | disclosed |
| US-5707989-A | ANTITUMOR AGENTS, INHIBITING SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | DR. KARL THOMAE GMBH (DE) | 1998-01-13 | — | — | US | disclosed |
| EP-0779888-A1 | PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | Dr. Karl Thomae GmbH (DE) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007657-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198380-A1 | Process for preparing 4,6-diaminopyrimido[5,4-d]pyrimidines | DPYD, DUT, DCTD | EGFR 1639/4885MKNK2 3705/4885CLK4 3782/4885 |
| US-20040059114-A1 | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | DPYD, DCK, DTYMK | EGFR 465/4885MKNK2 502/4885CLK4 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.